This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
1,4-DMAA
1,4-Dimethylamylamine (5-methylhexan-2-amine) | positional isomer of 1,3-DMAA that surfaced in U.S. supplements as a banned-substance dodge after FDA enforcement against the parent compound
Aliases (10)
Overview
What is 1,4-DMAA?
1,4-DMAA (1,4-dimethylamylamine; IUPAC name 5-methylhexan-2-amine) is a synthetic aliphatic primary amine and the positional isomer of 1,3-DMAA (geranamine / methylhexanamine). The two molecules share an identical empirical formula (C7H17N, MW 115.22) and differ only in where the second methyl branch sits along the carbon chain. Unlike 1,3-DMAA — which had a 50+ year pharmaceutical history as the nasal decongestant Forthane (Eli Lilly, 1944) before being rediscovered as a supplement stimulant in the 2000s — 1,4-DMAA has never been used as a pharmaceutical drug at any point. It surfaced in the U.S. dietary-supplement marketplace around 2017 as a successor stimulant after FDA enforcement against 1,3-DMAA, identified by Cohen et al. 2018 as an undeclared adulterant in commercial pre-workouts at 21-94 mg per serving. FDA treats it as illegal under the same 'not a dietary ingredient' framework that the 11th Circuit affirmed for 1,3-DMAA in 2019; WADA's S6 catch-all language covers it as a structural analogue.
Key Benefits
None established. There are no published human pharmacokinetic studies, no efficacy studies, no target-receptor binding data, and no anecdotal reports clean enough to credit (most users took it as part of undisclosed stim cocktails alongside 1,3-DMAA, octodrine, deterenol, or DMBA). The presumed subjective profile, by class extrapolation, is alertness + mild euphoria + focused drive at recreational-sympathomimetic cost — but the 1,4 positional isomer is structurally predicted to be weaker per mg than the parent 1,3-DMAA at preserved peripheral cardiovascular cost, which is the worst possible efficacy:risk ratio in the class.
Mechanism of Action
Presumed catecholamine-releasing aliphatic amine acting as a substrate at NET/DAT (analogous to but markedly less potent than amphetamine); weak TAAR1 affinity; alpha-1 vasoconstriction via elevated NE pool. ALL mechanism claims for the 1,4 isomer are extrapolated from 1,3-DMAA pharmacology and the broader aliphatic-amine class — none are directly measured for 1,4-DMAA. The structural shift (methyls at 1,4 instead of 1,3) is predicted, by analogy to amphetamine and ephedrine isomer pairs, to reduce CNS potency 2-10x while preserving peripheral cardiovascular effects.
Pharmacokinetics
Peptide Interactions
Stacking unstudied stimulants with anything is a gray-zone harm-multiplier.
additive cardiovascular load, additive anxiogenic potential
(ephedrine, synephrine, yohimbine, octopamine, octodrine, DMHA, 1,3-DMAA, 1,3-DMBA — most of which co-occur in the same pre-workout products as 1,4-DMAA, oft…
theoretical hypertensive crisis risk
additive cardiovascular load with no clean cognitive return
theoretical serotonin syndrome risk despite weak SERT affinity, real noradrenergic-overload risk
sympathomimetics impair thermoregulation and obscure cardiovascular warning signs
Quality Indicators
Per-serving dose varies >4x across seized products
Cohen 2018 found 21-94 mg per serving across commercial brands. There is no good-manufacturing-practice path for the molecule; whatever lab is supplying the API is dumping it into pre-workouts at concentrations driven by source-material variability, not titrated dose.
Co-formulated with undeclared stimulant cocktails
Cohen 2021 showed multi-stimulant blends including 1,4-DMAA + 1,3-DMAA + octodrine + deterenol in single products, often without label disclosure. Buyers cannot reliably get just the molecule.
No legitimate pharmaceutical-grade source exists
1,4-DMAA has never been approved as a drug in any jurisdiction. There is no compounding-pharmacy path, no Rx route, no FDA-bulk-substance listing. All available product is gray-market by definition.
Brand rotation as enforcement-evasion strategy
The 1,3-DMAA -> 1,3-DMBA -> DMHA -> octodrine -> 1,4-DMAA succession over 2013-2021 reflects deliberate analogue rotation to evade FDA enforcement. Brand families that sell 1,4-DMAA today have a track record of swapping in newer-still analogues without notice.
Counterfeit / mislabeled product is the norm, not the exception
Across DMAA-family analytical surveys, label-claim accuracy is <50%. Some products labeled 'DMAA' actually contain 1,4-DMAA or DMBA; some labeled '1,4-DMAA' contain 1,3-DMAA or stim cocktails.
What to Expect
- Onset30-60 min orally
- Peak1-3 hours
Side Effects & Safety
The full risk profile is inferential — drawn from the 1,3-DMAA literature plus the broader sympathomimetic-aliphatic-amine class. Assume at minimum equivalent risk to 1,3-DMAA.
Cardiovascular (highest-priority concern)
- Hypertensive episodes at recreational doses — additive with caffeine, exercise sympathetic load, dehydration
- Tachycardia / palpitations — universal at supratherapeutic doses
- Documented cardiac arrest in the parent compound (Eliason 2012 case reports for 1,3-DMAA) — combat athletes training at high heart rate are the worst-case use scenario
- Cerebral hemorrhage — multiple case reports for 1,3-DMAA; no published cases for 1,4-DMAA yet, but the absence likely reflects under-reporting (labs aren't routinely testing for 1,4-DMAA in tox screens) rather than a safer profile
- Cardiomyopathy risk on chronic use — the class as a whole accumulates myocardial strain similarly to amphetamine; chronic 1,4-DMAA use would reasonably be expected to do the same
Neuropsychiatric
- Anxiety, agitation, insomnia — universal at recreational doses, worse than caffeine
- Mood lability, irritability — particularly during the comedown
- Dependence potential — class-typical reinforcing properties; lower abuse liability than amphetamine but real
Other
- Hyperthermia under exercise load — sympathomimetics impair thermoregulation; combat-sport / endurance use is the highest-risk context
- Drug interactions — additive with caffeine, MAOIs (theoretical hypertensive crisis), other stimulants, SSRIs (theoretical serotonin destabilization despite weak SERT affinity)
- Unknown unknowns from the unstudied positional isomer status — toxicology hasn't been characterized
Specific watch periods
- There is no "safe break-in window" for an unstudied stimulant. The first dose is the most dangerous because tolerance to cardiovascular effects develops more slowly than tolerance to subjective effects, and the sourcing (see below) means the actual dose may be 2-4× the label claim.
References
Cohen PA, Travis JC, Keizers PHJ, Deuster P, Venhuis BJ. 2018 — Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin Toxicol 56(6):421-426. PMID 29115866
landmark identification of 1,4-DMAA as an unauthorized supplement adulterant; per-serving range 21-94 mg.
View StudyCohen PA, Travis JC, Vanhee C, Ohana D, Venhuis BJ. 2021 — Nine prohibited stimulants found in sports and weight loss supplements. Clin Toxicol 59(11):975-981. PMID 33755516
confirms 1,4-DMAA persistence in U.S. supplements four years post-identification, often as part of multi-stimulant cocktails.
View StudySchilling BK, Hammond KG, Bloomer RJ, Presley CS, Yates CR. 2013 — Physiological and pharmacokinetic effects of oral 1,3-dimethylamylamine administration in men. BMC Pharmacol Toxicol 14:52. PMID 24090077
only published human PK study for the parent 1,3 isomer; 1,4-DMAA pharmacology is extrapolated from this work.
View StudyEliason MJ, Eichner A, Cancio A, Bestervelt L, Adams BD, Deuster PA. 2012 — Case reports: Death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamylamine (DMAA). Mil Med 177(12):1455-9. PMID 23397688
military-context cardiac arrest case reports that drove DoD's Operation Supplement Safety; cardiovascular risk relevant to the 1,4 isomer by class extrapolation.
View StudyFDA — DMAA in Products Marketed as Dietary Supplements
FDA's central regulatory page on DMAA + analogues.
View StudyUnited States v. Hi-Tech Pharmaceuticals, Inc., 11th Cir. 2019 — Justia case page
the controlling federal appellate precedent; held DMAA is not a dietary ingredient under DSHEA. Logic applies to 1,4-DMAA isomer.
View StudyOPSS — DMAA: A prohibited stimulant
DoD Operation Supplement Safety summary covering DMAA + isomers.
View StudyWADA — 2026 Prohibited List
S6 stimulant category; methylhexanamine entry covers positional isomers via "similar chemical structure or similar biological effects" catch-all language.
View StudyUSADA — 2026 WADA Prohibited List Athlete Advisory
accessible summary of 2026 changes.
View StudyMethylhexanamine — Wikipedia
overview of 1,3-DMAA pharmaceutical history (Forthane/Eli Lilly), regulatory timeline, and structural family.
View Study1,4-Dimethylamylamine — Wikipedia
basic chemical identity for the 1,4 positional isomer; confirms it has never been pharmaceuticalized.
View StudyPubChem CID 34204 — 5-Methyl-2-hexylamine
formal chemical entry; CAS 28292-43-5, MW 115.22, formula C₇H₁₇N.
View StudyPharmacokinetic and Toxicological Aspects of 1,3-Dimethylamylamine with Clinical and Forensic Relevance (MDPI 2023)
modern toxicology synthesis for the 1,3 isomer; 1,4-DMAA addressed by class extrapolation.
View StudyJAMA Internal Medicine 2013 — Availability of DMAA Supplements Despite US Food and Drug Administration Action
early documentation of marketplace persistence post-FDA action; predicted the analog-substitution pattern that produced 1,4-DMAA.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.